Q-Line Biotech

Why is Q-Line Biotech falling/rising?

As of 12-Jun, Q-Line Biotech Ltd's stock price is rising to 509.30, up 0.98%, driven by a 2.92% increase over the past week. Despite some concerns, including a decline in investor participation and proximity to its 52-week high, the stock shows a positive trend overall.

As of 12-Jun, Q-Line Biotech Ltd's stock price is rising, currently at 509.30, with a change of 4.95 (0.98%) upward. This increase can be attributed to the stock's performance over the past week, where it has risen by 2.92%, outperforming the Sensex, which only increased by 1.10% during the same period. Additionally, the stock is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a positive trend in its price movement.<BR><BR>However, it's important to note that while the stock is currently rising, there are some concerning factors. The stock is 3.85% away from its 52-week high of Rs 528.9, and it has underperformed its sector by 2.92% today. Furthermore, there has been a decline in investor participation, with delivery volume falling by 17.13% compared to the 5-day average. Despite these negative indicators, the overall upward movement in price suggests that the stock is currently experiencing a rise.

Which are the latest news on Q-Line Biotech?

What does Q-Line Biotech do?

Q-Line Biotech Ltd is a small-cap healthcare services company, formerly known as POCT Services Private Limited, with a market cap of INR 1,199 Cr. It has no recent sales or profit data, a P/E ratio of 46.00, and a debt-equity ratio of 0.62.

Overview:<BR>Q-Line Biotech Ltd operates in the healthcare services industry and is categorized as a small-cap company.<BR><BR>History:<BR>Q-Line Biotech Ltd was originally incorporated as "POCT Services Private Limited" in 2010. The company changed its name to "Q-Line Biotech Private Limited" on July 23, 2021. There is no sales or profit data available for the latest quarter.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: N/A<BR>Most recent Net Profit: N/A<BR>Market-cap value: INR 1,199 Cr (Small Cap)<BR><BR>Key Metrics:<BR>P/E: 46.00<BR>Industry P/E: 92<BR>Dividend Yield: 0.00%<BR>Debt-Equity: 0.62<BR>Return on Equity: 12.91%<BR>Price-to-Book: 6.22<BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A<BR>Email: N/A<BR>Website: N/A

Who are the peers of the Q-Line Biotech?

Q-Line Biotech's peers include Suven Life Sciences, Vimta Labs, Krsnaa Diagnostics, and others. Management risk varies from excellent to below average, with Suven Life Sciences showing the highest 1-year return at 6.73% and Laxmi Dental the lowest at -48.54%.

Peers: The peers of Q-Line Biotech are Suven Life Scie., Vimta Labs, Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental, Tarsons Products, 3B Blackbio, Health X Platfor, and One Global Serv.<BR><BR>Quality Snapshot: Excellent management risk is observed at Vimta Labs, Krsnaa Diagnost., and Suraksha Diagno., while Average management risk is found at Laxmi Dental, 3B Blackbio, and One Global Serv, and the rest have Below Average management risk. Good growth is noted at Suraksha Diagno. and Laxmi Dental, while Average growth is seen at Health X Platfor, and the rest have Below Average growth. Excellent capital structure is present at Vimta Labs, Krsnaa Diagnost., Laxmi Dental, 3B Blackbio, and Health X Platfor, while Good capital structure is observed at Suraksha Diagno., and the rest have Below Average capital structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Suven Life Scie. at 6.73%, while the lowest is Laxmi Dental at -48.54%. Q-Line Biotech's 1-year return is not available for comparison. Additionally, Krsnaa Diagnost., Suraksha Diagno., Laxmi Dental, Tarsons Products, and Health X Platfor all have negative six-month returns.